为营造浓厚的学术氛围，由我校研究生院、党委研究生工作部主办、第一附属医院承办的研究生“名师名家讲坛”，将邀请台湾China Medical University Mien-Chie Hung教授来我校作学术报告。欢迎广大师生积极参加！

报告主题∶Marker guided target therapy

报告人：Mien-Chie Hung教授

报告时间∶2024年7月30日（周二）下午15∶30—17：30

报告地点：郑州大学东校区图书馆大礼堂

报告人简介：

Mien-Chie Hung, Ph.D. is the President for China Medical University in Taiwan. He was vice president for basic research, and held a Distinguished Endowed Chair of the Department of Molecular and Cellular Oncology at The University of Texas MD Anderson Cancer Center. He is a basic scientist with a keen translational vision and especially his recent research effort has significantly contributed to understanding the biology of cancer and to developing combinational cancer therapies to overcome resistance. He has published more than 640 peer-reviewed articles. His lifetime h-index reaches to 173 (Google Scholar) and 151 (Scopus), respectively. He is one of members of Selection Committee for Tang Prize in Biopharmaceutical Science category and is one of the founding Editorial Members for Cancer Cell (2002-2020), serves as Molecular Cell Advisory Board Member (2020-present); Cancer Research Senior Editor (2018-2021); American Journal for Cancer Research (AJCR) Editor-in-Chief (2015-2017; 2020-present); Cancer and Metastasis Reviews Editor (2018-present),Cancer Letters Senior Editor (2024-present), etc. Dr. Hung was appointed as an Academician of the Academia Sinica in Taiwan in 2002, elected as a Fellow in the Biological Sciences section of the American Association for the Advancement of Science in 2010, and later honored as a Fellow of The World Academy of Sciences (TWAS) for the Advancement of Science in Developing Countries in 2023.His research interests are focused on:1) Elucidation of non-canonical signal pathways of Receptor Tyrosine Kinases and novel posttranslational modifications that play critical roles in tumor progression; 2) Identification of crosstalk signaling pathways to understand drug resistance mechanisms for targeted therapy then develop effective therapy to overcome drug resistance; 3) Development of effectively immunotherapy and study of resistant mechanisms of immunotherapy.

研究生院

党委研究生工作部

第一附属医院

第一临床医学院

2024年7月29日